THE RACE TO DISCOVER NEW DRUGS RAMPS UP AT USC
USC Trojan Family Summer Issue 2018
MR. GARY HUTCHINSON INDUCTED INTO MEDICAL AND BIOLOGICAL ENGINEERING ELITE
April 9, 2018
WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Gary E. Hutchinson, President/CEO of Biothelium, Inc., and Entrepreneur in Residence, Alfred E. Mann Institute for Biomedical Engineering, University of Southern California to its College of Fellows. Mr. Hutchinson was nominated, reviewed, and elected by peers and members of the College of Fellows for outstanding contributions of advocacy and commercial development for cardiology, patient safety and identification, and cancer therapeutic devices.
Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”
A formal induction ceremony was held during the AIMBE Annual Meeting at the National Academy of Sciences in Washington, DC on April 9, 2018. Mr. Hutchinson was inducted along with 156 colleagues who make up the AIMBE College of Fellows Class of 2018.
AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. AIMBE’s mission is to recognize excellence, advance the public understanding, and accelerate medical and biological innovation. No other organization can bring together academic, industry, government, and scientific societies to form a highly influential community advancing medical and biological engineering. AIMBE’s mission drives advocacy initiatives into action on Capitol Hill and beyond.
For more information about the AIMBE, please visit www.aimbe.org.
BURNING TUMORS AWAY
April 9, 2018
A SUCCESSFUL MODEL FOR ACCELERATING MEDICAL INNOVATION
December 15, 2017
SoCalBio CONFERENCE SHOWCASES EMERGING TECHNOLOGY CREATED BY TROJANS
Biotech and Digital Health Companies with USC Ties Turn Out at Bioscience Event
October 2, 2017
Harsh Vathsangam ’13 is co-founder of Moving Analytics, a company featured at the SoCalBio Conference.
Cardiopulmonary patients fare much better if they complete cardiac rehab after hospitalization, but only about a third do so. That could change, thanks to work by Harsh Vathsangam ’13 and his company, Moving Analytics, which helps patients complete much of their cardiac rehab at home with an app-based program.
“We’ve tripled participation rates, especially among military veterans,” Vathsangam said during his presentation at the 19th Annual SoCalBio Conference, an event held Sept. 29 in Long Beach that showcased life-science companies and technologies.
Moving Analytics was founded by Vathsangam and two fellow USC graduates. It’s one of six biotech, diagnostic and digital health companies with strong USC ties that were featured at the event.
“We’re here to raise the next round of funding, and to get feedback and connect with investors, hospitals and providers that can help us build up and scale,” said Rahul Jain, associate professor of engineering at the USC Viterbi School of Engineering and co-founder of Vivace Systems.
Jain also serves as a mentor with USC’s Health, Technology and Engineering, a program — part of the USC biotech pipeline — that helps to create student startups and facilitate their progress. HTE students provided patent research and market analysis for Thermal View Monitoring, CaliVive and LiTE Vectors — three companies featured at the conference.
“HTE gave us access to connections and resources, including people from the FDA (Food and Drug Administration),” Vathsangam said. “We learned about venture capital, licensing, market segments and funding. We also learned how to best navigate the regulatory environment of running a health care company.”
From bench to market
The SoCalBio Conference brings entrepreneurs, investors, researchers and service providers together every year.
“It’s a chance for AMI and USC to pitch early stage programs and companies and also to network with potential investors,” said Jon Lasch, executive director for the Alfred E. Mann Institute for Biomedical Engineering at USC.
AMI, a platinum sponsor of the event, supports researchers who take biotech from lab to market. AMI helps navigate regulatory pathways, organize clinical studies, build prototypes, form companies and raise capital.
“AMI covers a lot of biomed research out of USC, and this event helps us find who’s doing what, who’s out there,” said Winn Hong, senior director of engineering and business development at AMI. “It helps us draw a roadmap of who the players are, and if there’s synergy, perhaps we can work with them. Everyone’s here to get a take on the pulse of the biomed field.”
Looking forward to a biotech park
USC is committed to creating a biotech park on the Health Sciences Campus, a vision that’s creating a buzz at events like the SoCalBio Conference. A biotech park would create quality jobs for L.A.’s Eastside neighborhoods and advance community health. With its proximity to the Health Sciences Campus, a biotech park on the Eastside would also have the benefit of physician input.
“Having a university-level facility means physicians will be there to figure out how to make the tech relevant,” Lasch said. “A biotech park will bring like-minded people in the industry together to work as a critical mass to address some of the more important medical problems we face today.”
The biotech park would also provide space for startups and established companies like Moving Analytics.
“Being plugged in to the community at the biotech park would be great,” Vathsangam said. “It helps when you want to develop ideas and when you want to recruit new graduates. I’d like to see a few advanced companies move into that kind of space so you could have the benefit of mentorship.”
AMI-USC WILL BE A PLATINUM SPONSOR OF THE SOUTHERN CALIFORNIA BIOMEDICAL COUNCIL ANNUAL INVESTOR CONFERENCE
September 14, 2017
AMI-USC (The Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California), a non-profit organization that bridges the gap between biomedical invention and the creation of commercially successful medical devices that save and improve people’s lives, announced today that it will be a platinum sponsor of the 19th Annual SoCalBio Conference in Long Beach on September 29th.
Jon Lasch, AMI-USC’s Executive Director said, “Southern California Biomedical Council (SoCalBio) is a nonprofit, member-supported trade association that serves the biotech, medtech, IVD and digital health communities in the six counties that comprise the Greater Los Angeles region (Los Angeles, Orange, Ventura, Santa Barbara, Riverside and San Bernardino). We sponsor this conference because what they do – showcasing value-based bioscience innovations and exploring efficient pathways to bring them to market – lines up really well with what we do. It is also great to keep up with what Biomedical innovators are doing and share with them what we are doing.”
PROA MEDICAL, INC. ENTERS INTO STRATEGIC ALLIANCE AND NATIONWIDE DISTRIBUTION AGREEMENT WITH A LEADING WOMEN’S HEALTH DISTRIBUTOR
June 27, 2017
AMI-USC (The Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California), a non-profit organization that bridges the gap between biomedical invention and the creation of commercially successful medical devices that save and improve people’s lives, announced today that Proa Medical, Inc., an AMI-USC spinout company focused on women’s health medical devices, entered into a strategic alliance and nationwide distribution agreement with a leading women’s health distributor.
Arman Nadershahi, AMI-USC’s Senior Corporate and Intellectual Property Counsel, and CEO of Proa Medical, Inc., said, “We are excited to have formally entered into a long-term relationship with a preeminent distributor of obstetrical products. Our distributor has committed to investing considerable resources to market and sell Proa Medical’s innovative Brella Vaginal Retractor to hospitals throughout the US.”
The Brella Vaginal Retractor is a patented, single-use retractor with a built-in light source designed to provide optimal visualization and access during vaginal or perineal wound repair. The Brella lighted retractor separates the edges of the vagina, provides interior illumination, holds back tissue (including deep vaginal walls), and may reduce the incidence of needle stick injuries. Proa Medical, Inc. has received positive feedback from obstetricians and repeat hospital orders in its initial test launch.
About Proa Medical, Inc.
Proa Medical, Inc. provides a rapid and efficient channel to commercialize novel medical devices for women’s health that are easier to use, safer, and more efficient. As a spinout of the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California (USC), the company was founded to help physician-inventors efficiently bring to market innovative, practice-enhancing technologies.
37 ºC 2017 OSLO, NORWAY CONFERENCE – JON LASCH PRESENTATION
June 6, 2017
Jon’s presentation may also be viewed here.
NANOENGINEERED STENT SURFACE TO REDUCE IN-STENT RESTENOSIS IN VIVO
June 2, 2017
VAROCTO RECEIVES APPROVAL FOR 3 PRODUCTS FROM CHINESE FDA
June 2, 2017
AMI-USC (The Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California), a non-profit organization that bridges the gap between biomedical invention and the creation of commercially successful medical devices that save and improve people’s lives, announced today that Varocto, Inc., an AMI ophthalmology spinout, received approval for 3 of its products from the Chinese equivalent of the FDA.
Winn Hong, AMI-USC’s Sr. Director for Engineering and Business Development, and Interim CEO of Varocto, said, “We are happy to report that Varocto’s products for high-resolution, non-invasive, retinal angiography have been approved by the Chinese FDA. These products include optical coherence tomography (OCT) hardware, angiography software, and a combination of the two. The products will help prevent blindness, through early diagnosis, in people with diabetic retinopathy, macular degeneration, macular edema and other potentially blinding diseases. The big news is that these products are part of a platform technology that mitigates these problems non-invasively in less than 2 minutes.”
AIMBE HAS ELECTED SEVEN FELLOWS FROM AMI-USC
May 18, 2017
AMI-USC (The Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California), a non-profit organization that bridges the gap between biomedical invention and the creation of commercially successful medical devices that save and improve people’s lives, announced today that the American Institute for Medical and Biological Engineering (AIMBE), a non-profit organization headquartered in Washington, DC that represents the top 2% of medical and biological engineers, elected seven of USC-AMI’s associates as fellows.
Jon Lasch, AMI-USC’s Executive Director said, “We are very happy and proud to report that AIMBE elected Cesar Blanco and Molly Schmid as Fellows. They join Scott Fraser, Rob Greenberg, David Hankin, Tom Lobl, and myself, who were previously elected. This is a great honor and very important since AIMBE helps to shape healthcare policy in the US and around the world.”